Sangamo Therapeutics Inc (NASDAQ:SGMO) CFO Kathy Yi sold 5,000 shares of Sangamo Therapeutics stock in a transaction dated Monday, September 17th. The stock was sold at an average price of $14.66, for a total value of $73,300.00. Following the completion of the transaction, the chief financial officer now directly owns 12,250 shares in the company, valued at approximately $179,585. The sale was disclosed in a document filed with the SEC, which is available at this link.

Kathy Yi also recently made the following trade(s):

  • On Thursday, August 16th, Kathy Yi sold 5,000 shares of Sangamo Therapeutics stock. The stock was sold at an average price of $15.39, for a total value of $76,950.00.
  • On Monday, July 16th, Kathy Yi sold 5,000 shares of Sangamo Therapeutics stock. The stock was sold at an average price of $14.77, for a total value of $73,850.00.

NASDAQ:SGMO traded up $0.26 on Friday, hitting $14.00. 1,691,988 shares of the company’s stock traded hands, compared to its average volume of 2,282,169. The company has a debt-to-equity ratio of 0.07, a current ratio of 7.24 and a quick ratio of 7.24. Sangamo Therapeutics Inc has a 1 year low of $11.30 and a 1 year high of $27.50. The stock has a market cap of $1.72 billion, a PE ratio of -20.00 and a beta of 2.97.

Sangamo Therapeutics (NASDAQ:SGMO) last released its earnings results on Wednesday, August 8th. The biopharmaceutical company reported ($0.17) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.15) by ($0.02). The business had revenue of $21.42 million for the quarter, compared to analysts’ expectations of $21.43 million. Sangamo Therapeutics had a negative net margin of 105.65% and a negative return on equity of 26.36%. The company’s revenue was up 159.6% compared to the same quarter last year. During the same period last year, the firm earned ($0.17) EPS. On average, equities research analysts anticipate that Sangamo Therapeutics Inc will post -0.69 earnings per share for the current year.

Several equities analysts have weighed in on the company. BidaskClub raised Sangamo Therapeutics from a “sell” rating to a “hold” rating in a research note on Wednesday, June 20th. Guggenheim assumed coverage on Sangamo Therapeutics in a research note on Tuesday. They set a “buy” rating and a $18.00 target price on the stock. Zacks Investment Research raised Sangamo Therapeutics from a “strong sell” rating to a “hold” rating in a research note on Tuesday, July 24th. Wedbush reaffirmed a “hold” rating and set a $9.00 target price on shares of Sangamo Therapeutics in a research note on Tuesday, July 24th. Finally, ValuEngine cut Sangamo Therapeutics from a “strong-buy” rating to a “buy” rating in a research note on Thursday, September 6th. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating and eight have given a buy rating to the company’s stock. The company presently has an average rating of “Buy” and an average price target of $20.57.

Several hedge funds and other institutional investors have recently made changes to their positions in the stock. United Services Automobile Association grew its stake in shares of Sangamo Therapeutics by 9.2% in the 2nd quarter. United Services Automobile Association now owns 57,633 shares of the biopharmaceutical company’s stock valued at $818,000 after buying an additional 4,860 shares in the last quarter. Northern Trust Corp grew its stake in shares of Sangamo Therapeutics by 21.0% in the 2nd quarter. Northern Trust Corp now owns 1,287,800 shares of the biopharmaceutical company’s stock valued at $18,286,000 after buying an additional 223,870 shares in the last quarter. Bain Capital Public Equity Management LLC bought a new stake in shares of Sangamo Therapeutics in the 2nd quarter valued at approximately $2,002,000. Advisors Asset Management Inc. grew its stake in shares of Sangamo Therapeutics by 305.3% in the 2nd quarter. Advisors Asset Management Inc. now owns 21,187 shares of the biopharmaceutical company’s stock valued at $301,000 after buying an additional 15,960 shares in the last quarter. Finally, Mount Yale Investment Advisors LLC grew its stake in shares of Sangamo Therapeutics by 2,202.8% in the 2nd quarter. Mount Yale Investment Advisors LLC now owns 8,359 shares of the biopharmaceutical company’s stock valued at $119,000 after buying an additional 7,996 shares in the last quarter. 63.84% of the stock is owned by institutional investors and hedge funds.

Sangamo Therapeutics Company Profile

Sangamo Therapeutics, Inc focuses on translating science into genomic therapies that transform patients' lives using platform technologies in genome editing, gene therapy, gene regulation, and cell therapy. The company's zinc finger DNA-binding protein (ZFP) technology enables specific genome editing and gene regulation.

Featured Article: Short Selling Stocks and Day Traders

Insider Buying and Selling by Quarter for Sangamo Therapeutics (NASDAQ:SGMO)

Receive News & Ratings for Sangamo Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sangamo Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.